Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 5211-5220 Newer>

The Motley Fool October 30, 2008 Brian Orelli	What's on Deck for AstraZeneca? The drugmaker increases EPS by cutting costs, but it's the next move that will count the most.
The Motley Fool October 30, 2008 Brian Orelli	Not What the Doctor Ordered Biogen reports a third case of a deadly brain disorder since their multiple sclerosis drug Tysabri made its return.
Chemistry World October 27, 2008 James Mitchell Crow	Viagra variants could beat muscle fatigue The extreme fatigue that muscular dystrophy patients suffer after gentle exercise could be treated with longer-acting variants of sildenafil (Viagra), US scientists say.
The Motley Fool October 27, 2008 Brian Orelli	Hansen Medical Bucks the Trend The credit crunch doesn't seem to be having much of an effect on Hansen's ability to sell its products to hospitals.
Chemistry World October 24, 2008 Matt Wilkinson	Europe suspends anti-obesity drug The European drugs watchdog, European Medicines Agency, has recommended that doctors stop prescribing Sanofi-aventis' anti-obesity drug rimonabant, because the risk of side effects is too high.
The Motley Fool October 24, 2008 Brian Orelli	Affymetrix Has Trouble Turning Around The problem is that Affymetrix doesn't sell sequencers, and no one seems to want the genome and RNA analyzers that it does sell.
The Motley Fool October 24, 2008 Brian Orelli	Lilly's Results Run the Gamut The company's GAAP EPS and adjusted EPS are at polar extremes.
The Motley Fool October 24, 2008 Brian Orelli	Elan's Approaching the Black Elan doesn't have positive cash flow yet, but it's getting closer, with revenue and expenses headed in the right direction.
The Motley Fool October 24, 2008 Brian Orelli	Amgen's Back Shares of Amgen are up 40% from their lows in March. And for good reason.
BusinessWeek October 23, 2008 John Carey	Reading the Entire Genetic Code Pioneers such as 23andMe and Navigenics use snips of genes to make medical predictions. Now new tools from more start-ups are on the horizon.
<Older 5211-5220 Newer> Return to current articles.